Citations

Showing 10 of 108152 citations.

Palliative care utilization in calciphylaxis: a single‐center retrospective review of 121 patients (1999–2016)
Gaster, Emily E., Riemer, Christie , Aird, Jenna L., King, Brian J. , Wilson, Barbara, Strand, Jacob J. , Wu, Kelly L. , Cleary, James F. , Lohse, Christine M. , Lehman, Julia S. , Riemer, Christie A, El-Azhary, Rokea A, Wu, Kelly L , Lehman, Julia S , Gaster, Emily E, Aird, Jenna, el‐Azhary, Rokea A.

Mayo Clinic

International Journal of Dermatology | July 2, 2021 | Volume: 61 | Issue: 4 | Pages: 455-460

10.1111/ijd.15726 | PMID 34196998 Get It

AbstractBackgroundCalciphylaxis is a debilitating dermatological condition associated with high rates of morbidity and mortality. Palliative care offers a multidisciplinary approach to addressing symptoms and goals of care in patients with serious medical diagnoses. Involvement of palliative services for calciphylaxis is infrequently reported in the literature. The purpose of this report is to assess rates of palliative and pain consultation for patients with calciphylaxis.MethodsThis is a comprehensive, single‐institution retrospective chart review of 121 eligible patients with a diagnosis of calciphylaxis treated at Mayo Clinic in Rochester, Minnesota, from 1999 to 2016. Inclusion criteria were an indisputable diagnosis of calciphylaxis based on clinical, histopathologic, and radiographic features. One hundred twenty‐one patients met inclusion criteria.ResultsFifty‐one patients (42%) received either a palliative (n = 15) or pain (n = 20) consultation, or both (n = 16). Patients with a palliative care consultation were younger compared with those without (mean ages 57 vs. 62 years, P = 0.046). In 104 patients (86%), psychiatric symptoms were not assessed.ConclusionsIn this cohort of patients with calciphylaxis, the majority do not receive palliative and pain care consultations. Psychiatric complications are inconsistently addressed. These observations highlight practice gaps in the care of patients with calciphylaxis.
Clinical utility of brain biopsy for presumed CNS relapse of systemic lymphoma
Brown, Desmond A., Goyal, Anshit, Richter, Kent R., Haglin, Jack M., Himes, Benjamin T., Lu, Victor M., Snyder, Kendall, Hughes, Joshua, Decker, Paul A., Opoku-Darko, Michael, Link, Michael J., Burns, Terry C., Parney, Ian F., Brown, Desmond A., Goyal, Anshit, Richter, Kent R., Haglin, Jack M., Himes, Benjamin T., Lu, Victor M., Snyder, Kendall, Hughes, Joshua, Decker, Paul A., Opoku-Darko, Michael, Link, Michael J., Burns, Terry C., Parney, Ian F.

Mayo Clinic

Journal of Neurosurgery | July 2, 2021 | Volume: 136 | Issue: 1 | Pages: 30-39

10.3171/2020.12.jns202517 | PMID 34214988 Get It

OBJECTIVE The objective of this study was to determine the frequency with which brain biopsy for presumed CNS relapse of systemic hematological malignancies yields new, actionable diagnostic information. Hematological malignancies represent a disparate group of genetic and histopathological disorders. Proclivity for brain involvement is dependent on the unique entity and may occur synchronously or metasynchronously with the systemic lesion. Diffuse large B-cell lymphomas (DLBCLs) have a high propensity for brain involvement. Patients in remission from systemic DLBCL may present with a lesion suspicious for brain relapse. These patients often undergo brain biopsy. The authors’ a priori hypothesis was that brain biopsy in patients with a history of systemic DLBCL and a new brain MRI lesion would have lower diagnostic utility compared with patients with non-DLBCL systemic malignancies. METHODS The authors performed a retrospective review of patients who underwent brain biopsy between 2000 and 2019. Inclusion criteria were patients ≥ 18 years of age with a prior systemic hematological malignancy in remission presenting with a new brain MRI lesion concerning for CNS relapse. Patients with a history of any CNS neoplasms, demyelinating disorders, or active systemic disease were excluded. The main outcome was the proportion of patients with a distinct histopathological brain diagnosis compared with the systemic malignancy. The authors secondarily assessed overall survival, procedure-related morbidity, and 30-day mortality. RESULTS Sixty patients met inclusion criteria (40 males and 20 females); the median age at brain biopsy was 67 years (range 23–88 years). The median follow-up was 8.5 months (range 0.1–231 months). Thirty-nine (65.0%) patients had DLBCL and 21 (35%) had non-DLBCL malignancies. Thirty-five of 36 (97.2%) patients with prior systemic DLBCL and a diagnostic biopsy had histopathological confirmation of the original systemic disease versus 0 of 21 patients with non-DLBCL systemic malignancies (p < 0.001). Morbidity and 30-day mortality were 8.3% and 10.0%, respectively; 2 of 6 30-day mortalities were directly attributable to the biopsy. The median overall survival following brain biopsy was 10.8 months. CONCLUSIONS Patients with a history of systemic DLBCL and presumed CNS relapse gained minimal clinical benefit from brain biopsy but were at high risk of morbidity and mortality. In patients with a history of non-DLBCL systemic malignancies, brain biopsy remained critical given the high likelihood for discovery of distinct diagnostic entities. It was determined that patients with a prior systemic DLBCL and presumed brain relapse should likely receive empirical therapy obviating treatment delay and the risks of brain biopsy.
Use of Cross-sectional and Perspective Mapping to Spatially and Statistically Represent Inpatient Glucose Control
Saulnier, George E., Castro, Janna C. , Mi, Lanyu , Cook, Curtiss B.

Mayo Clinic

Journal of Diabetes Science and Technology | July 2, 2021 | Volume: 16 | Issue: 6 | Pages: 1385-1392

10.1177/19322968211027230 | PMID 34210201 Get It

Background: The use of inpatient location for the depiction of glycemic control is an alternative approach to the traditional analysis of hospital-derived glucometric data. Our aim was to develop a method of spatial representation and to test for corresponding statistical variation in inpatient glucose control data. Methods: Point-of-care blood glucose data from inpatients with diabetes mellitus were extracted. Calculations included patient-day weighted means (PDWMs) and percentage of patient hospital days with hypoglycemia. Results were overlaid onto hospital floor plans, and room numbers were used as geolocators to generate cross-sectional (2-dimensional) and perspective (3-dimensional) views of the data. Linear mixed and mixed-effects logistic regression models were used to compare the location effect and to assess statistical variation in the data after adjusting for age, sex, and severity of illness. Results: Visual inspection of cross-sectional and perspective maps demonstrated variation in glucometric outcomes across areas within the hospital. Statistical analysis confirmed significant variation between some hospital wings and floors. Conclusions: Spatial depiction of glucometric data within the hospital could yield insights into hot spots of poor glycemic control. Future studies on how to operationalize this approach, and whether this method of analysis can drive changes in glycemic management practices, need to be conducted.
Interleukin-2 Transiently Inhibits Pulsatile Growth Hormone Secretion in Young but not Older Healthy Men
Roelfsema, Ferdinand , Yang, Rebecca , Veldhuis, Johannes D.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 2, 2021 | Volume: 106 | Issue: 10 | Pages: 2855-2864

10.1210/clinem/dgab484 | PMID 34212195 Get It

AbstractContextInterleukin-2 (IL-2), a proinflammatory cytokine, has been used to treat malignancies. Increased cortisol and adrenocorticotropin (ACTH) were noted, but growth hormone (GH) secretion was not investigated in detail.ObjectiveWe quantified GH secretion after a single subcutaneous injection of IL-2 in 17 young and 18 older healthy men in relation to dose, age, and body composition.MethodsThis was a placebo-controlled, blinded, prospectively randomized, crossover study. At 20:00 hours IL-2 (3 or 6 million units/m2) or saline was injected subcutaneously. Lights were off between 23:00 and 07:00 hours. Blood was sampled at 10-minute intervals for 24 hours. Outcome measures included convolution analysis of GH secretion.ResultsGH profiles were pulsatile under both experimental conditions and lower in older than young volunteers. Since the effect of IL-2 might be time limited, GH analyses were performed on the complete 24-hour series and the 6 hours after IL-2 administration. Total and pulsatile 24-hour GH secretion decreased nonsignificantly. Pulsatile secretion fell over the first 6 hours after IL-2 (P = .03), with visceral fat as a covariate (P = .003), but not age (P = .10). Plots of cumulative 2-hour bins of GH pulse mass showed a distinction by treatment and age groups: A temporary GH decrease of 32% and 28% occurred in the first 2-hour bins after midnight (P = .02 and .04) in young participants, whereas in older individuals no differences were present at any time point.ConclusionThis study demonstrates that IL-2 temporarily diminishes GH secretion in young, but not older, men.
Bioactive refinement for endosaccular treatment of intracranial aneurysms
Szatmáry, Zoltán , Mounier, Jérémy, Cortese, Jonathan, Couquet, Claude, Chaubet, Frédéric , Kadirvel, Ramanathan , Bardet, Sylvia M. , Rouchaud, Aymeric , Bardet, Sylvia M , Rouchaud, Aymeric , Janot, Kévin , Cortese, Jonathan , Mounayer, Charbel

Mayo Clinic

The Neuroradiology Journal | July 2, 2021 | Volume: 34 | Issue: 6 | Pages: 534-541

10.1177/19714009211024631 | PMID 34210195 Get It

Endovascular treatment is the first-line therapy for most intracranial aneurysms; however, recanalisation remains a major limitation. Developments in bioengineering and material science have led to a novel generation of coil technologies for aneurysm embolisation that address clinical challenges of aneurysm recurrence. This review presents an overview of modified surface coil technologies and summarises the state of the art regarding their efficacy and limitations based on experimental and clinical results. We also present potential perspectives to develop biologically optimised devices.
Interstitial amyloidosis in sporadic inclusion body myositis
Alamr, Mazen , Milone, Margherita , Naddaf, Elie , Ytterberg, Steven R. , Steel, Stephanie J., Liewluck, Teerin , Liewluck, T , Naddaf, Elie , Jones, Lyell K.

Mayo Clinic

Muscle & Nerve | July 2, 2021 | Volume: 64 | Issue: 5 | Pages: 590-594

10.1002/mus.27362 | PMID 34196979 Get It

Abstract Introduction/Aims Intracellular congophilic inclusions within muscle fibers, although nonspecific, are one of the pathological hallmarks of sporadic inclusion body myositis (sIBM). Extracellular amyloid deposits in muscle, on the other hand, are the canonical findings of amyloid myopathies, which occur with or without systemic amyloidosis. Methods We reviewed the muscle biopsy database (1998–2020) to identify sIBM patients with extracellular amyloid deposits. Clinical and laboratory data were reviewed. Results We identified five sIBM patients (three clinicopathologically defined and two clinically defined) with extracellular amyloid deposits in muscle. Mean age at diagnosis was 74.8 y (range, 68–84 y). All patients had a typical sIBM pattern of weakness without associated sensory or autonomic symptoms. None had electrophysiological evidence of peripheral neuropathy. Only one patient had a monoclonal gammopathy (immunoglobulin M‐lambda, IgM‐λ) with normal bone marrow biopsy. This patient with monoclonal gammopathy and three other patients underwent abdominal fat pad aspirate and were negative for amyloid. Cardiac evaluation was unrevealing in the four patients tested. Three patients without monoclonal gammopathy had normal transthyretin gene sequencing and inconclusive mass spectrometry‐based analysis. The patient with monoclonal gammopathy died of pneumosepsis 5 y after diagnosis and autopsy revealed multi‐organ transthyretin amyloidosis. Discussion Detection of extracellular amyloid deposition in muscle should trigger an aggressive search for systemic amyloidosis independently from other associated myopathological abnormalities. Amyloid subtyping is crucial for early therapy and mortality prevention. An isolated monoclonal gammopathy should not halt a search for non‐hematological causes of systemic amyloidosis.
Updated Experience of Mycobacterium chimaera Infection: Diagnosis and Management in a Tertiary Care Center
Tan, Nicholas Y. , Tarabochia, Alex D. , Wilson, John , Bagameri, Gabor, Bennett, Courtney , Saleh, Omar Abu , Bennett, Courtney E, Abu Saleh, Omar , DeSimone, Daniel C. , DeSimone, Christopher V.

Mayo Clinic

Open Forum Infectious Diseases | July 1, 2021 | Volume: 8 | Issue: 8 | Pages: No page available

10.1093/ofid/ofab348 | PMID 34377729 Get It

Abstract Background Despite safety communications from the Food and Drug Administration (FDA) regarding the outbreak of Mycobacterium chimaera infections (MCIs) from contaminated heater-cooler devices, new cases continue to be identified. Methods We retrospectively reviewed confirmed cases of MCI that were managed at Mayo Clinic sites (Arizona, Florida, and Minnesota) from 09/2015 to 01/2021. Clinical histories including prior cardiovascular surgery were recorded. Diagnostic workup including ophthalmologic examination, imaging, and laboratory testing was reviewed. Treatment and survival outcomes on follow-up were obtained. Results Twelve patients with MCI were included. All patients had aortic valve or graft replacement. Five patients had their surgical procedures following the 10/15/2015 FDA safety communication. The mean time from surgery to symptom onset (range) was 32 (13–73) months. Ten of 11 patients who underwent ophthalmologic examination had chorioretinal abnormalities. Three patients who underwent microbial cell-free deoxyribonucleic acid sequencing tested positive for M. chimaera, which was subsequently confirmed with blood culture growth. Echocardiography and positron emission tomography/computed tomography (PET/CT) revealed evidence of prosthetic valve/graft infection in 7/12 (58.3%) and 6/10 (60.0%) of cases, respectively. Seven patients (58.3%) underwent redo cardiovascular surgery. Of these, 1 patient died 2 days postdischarge, 1 experienced spinal osteomyelitis relapse, and another had interval prosthetic valve fluorodeoxyglucose (FDG) uptake on PET/CT suspicious for recurrent infection. Among 4 patients on medical therapy only, 3 expired or transitioned to hospice during follow-up. Conclusions MCI continues to occur despite the FDA communications. Incorporation of ophthalmologic examination and use of advanced tools may improve MCI diagnosis. The mortality in these patients is high even with aggressive surgical/medical management.
Mentorship, Sponsorship, and Coaching for Trainee Career Advancement
Balthazar, Patricia , Murphy, Alexandra , Tan, Nelly

Mayo Clinic

RadioGraphics | July 1, 2021 | Volume: 41 | Issue: 4 | Pages: E100-E102

10.1148/rg.2021210085 | PMID 34197251 Get It

Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis
Lambertini, Matteo , Blondeaux, Eva , Bruzzone, Marco , Perachino, Marta , Anderson, Richard A. , Azambuja, Evandro de , Poorvu, Philip D. , Kim, Hee Jeong , Villarreal‐Garza, Cynthia , Pistilli, Barbara , Vaz-Luís, Inês , Saura, Cristina , Ruddy, Kathryn J. , Franzoi, Maria Alice , Sertoli, Chiara, Azim, Hatem A. , Demeestere, Isabelle , Mastro, Lucia Del , Pagani, Olivia , de Azambuja, Evandro , Ceppi, Marcello , Azim, Hatem A , Amant, Frederic , Demeestere, Isabelle , Del Mastro, Lucia , Partridge, Ann H , Peccatori, Fedro A , Lambertini, Matteo , Saura, Cristina , Villarreal-Garza, Cynthia , Bruzzone, Marco , Amant, Frédéric , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | July 1, 2021 | Volume: 39 | Issue: 29 | Pages: 3293-3305

10.1200/jco.21.00535 | PMID 34197218 Get It

PURPOSE Many patients and physicians remain concerned about the potential detrimental effects of pregnancy after breast cancer (BC) in terms of reproductive outcomes and maternal safety. This systematic review and meta-analysis aimed at providing updated evidence on these topics. METHODS A systematic literature review was conducted to identify studies including patients with a pregnancy after BC (PROSPERO number CRD42020158324). Likelihood of pregnancy after BC, their reproductive outcomes, and maternal safety were assessed. Pooled relative risks, odds ratios (ORs), and hazard ratios (HRs) with 95% CIs were calculated using random effects models. RESULTS Of 6,462 identified records, 39 were included involving 8,093,401 women from the general population and 112,840 patients with BC of whom 7,505 had a pregnancy after diagnosis. BC survivors were significantly less likely to have a subsequent pregnancy compared with the general population (relative risk, 0.40; 95% CI, 0.32 to 0.49). Risks of caesarean section (OR, 1.14; 95% CI, 1.04 to 1.25), low birth weight (OR, 1.50; 95% CI, 1.31 to 1.73), preterm birth (OR, 1.45; 95% CI, 1.11 to 1.88), and small for gestational age (OR, 1.16; 95% CI, 1.01 to 1.33) were significantly higher in BC survivors, particularly in those with previous chemotherapy exposure, compared with the general population. No significantly increased risk of congenital abnormalities or other reproductive complications were observed. Compared to patients with BC without subsequent pregnancy, those with a pregnancy had better disease-free survival (HR, 0.66; 95% CI, 0.49 to 0.89) and overall survival (HR, 0.56; 95% CI, 0.45 to 0.68). Similar results were observed after correcting for potential confounders and irrespective of patient, tumor, and treatment characteristics, pregnancy outcome, and timing of pregnancy. CONCLUSION These results provide reassuring evidence on the safety of conceiving in BC survivors. Patients' pregnancy desire should be considered a crucial component of their survivorship care plan.